SG11202110469PA - Ghrh or analogues thereof for use in treatment of hepatic disease - Google Patents
Ghrh or analogues thereof for use in treatment of hepatic diseaseInfo
- Publication number
- SG11202110469PA SG11202110469PA SG11202110469PA SG11202110469PA SG11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA SG 11202110469P A SG11202110469P A SG 11202110469PA
- Authority
- SG
- Singapore
- Prior art keywords
- ghrh
- analogues
- treatment
- hepatic disease
- hepatic
- Prior art date
Links
- 101150102363 Ghrh gene Proteins 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826284P | 2019-03-29 | 2019-03-29 | |
| US201962861187P | 2019-06-13 | 2019-06-13 | |
| PCT/US2020/025180 WO2020205498A1 (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110469PA true SG11202110469PA (en) | 2021-10-28 |
Family
ID=72607731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110469PA SG11202110469PA (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10799562B1 (en) |
| EP (1) | EP3947426A4 (en) |
| JP (1) | JP2022527190A (en) |
| KR (1) | KR20210145226A (en) |
| CN (1) | CN113646327A (en) |
| AU (1) | AU2020253828A1 (en) |
| CA (1) | CA3133319A1 (en) |
| IL (1) | IL286703A (en) |
| SG (1) | SG11202110469PA (en) |
| WO (1) | WO2020205498A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205498A1 (en) | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009140731A (en) * | 2007-04-04 | 2011-05-10 | Тератекнолоджиз Инк. (Ca) | PHARMACEUTICAL COMPOSITIONS CONTAINING GHRH MOLECULES |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| WO2015100423A2 (en) * | 2013-12-24 | 2015-07-02 | University Of Miami | Methods for treating cancer with ghrh agonists |
| WO2017066619A1 (en) * | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
| MX2018012716A (en) * | 2016-04-19 | 2019-02-11 | Griffon Pharmaceuticals Inc | Pegylated bioactive peptides and uses thereof. |
| US20210059993A1 (en) * | 2018-02-14 | 2021-03-04 | Lumos Pharma, Inc. | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CN116801788A (en) * | 2020-10-30 | 2023-09-22 | 综合医院公司 | Kit, reagent and method for assessing liver disease |
| US20220152012A1 (en) * | 2020-11-16 | 2022-05-19 | The Regents Of The University Of California | Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof |
-
2020
- 2020-03-27 WO PCT/US2020/025180 patent/WO2020205498A1/en unknown
- 2020-03-27 US US16/832,128 patent/US10799562B1/en active Active
- 2020-03-27 KR KR1020217034940A patent/KR20210145226A/en unknown
- 2020-03-27 SG SG11202110469PA patent/SG11202110469PA/en unknown
- 2020-03-27 AU AU2020253828A patent/AU2020253828A1/en active Pending
- 2020-03-27 JP JP2021557925A patent/JP2022527190A/en active Pending
- 2020-03-27 CA CA3133319A patent/CA3133319A1/en active Pending
- 2020-03-27 EP EP20784029.9A patent/EP3947426A4/en active Pending
- 2020-03-27 CN CN202080025127.2A patent/CN113646327A/en active Pending
- 2020-09-11 US US17/018,878 patent/US10946073B2/en active Active
-
2021
- 2021-02-08 US US17/170,579 patent/US11738066B2/en active Active
- 2021-09-26 IL IL286703A patent/IL286703A/en unknown
-
2023
- 2023-07-12 US US18/351,169 patent/US20240091316A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240091316A1 (en) | 2024-03-21 |
| AU2020253828A1 (en) | 2021-10-28 |
| IL286703A (en) | 2021-10-31 |
| US10799562B1 (en) | 2020-10-13 |
| EP3947426A1 (en) | 2022-02-09 |
| EP3947426A4 (en) | 2023-01-04 |
| US20200405816A1 (en) | 2020-12-31 |
| KR20210145226A (en) | 2021-12-01 |
| US10946073B2 (en) | 2021-03-16 |
| JP2022527190A (en) | 2022-05-31 |
| US20210177943A1 (en) | 2021-06-17 |
| WO2020205498A1 (en) | 2020-10-08 |
| CA3133319A1 (en) | 2020-10-08 |
| CN113646327A (en) | 2021-11-12 |
| US11738066B2 (en) | 2023-08-29 |
| US20200306345A1 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3577135T3 (en) | A pharmaceutical composition for use in the treatment or prevention of c5-related diseases | |
| HRP20211272T8 (en) | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions | |
| IL274578A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| EP3398614A4 (en) | Agent for preventing and/or treating alzheimer's disease | |
| PL3285755T3 (en) | Creatine hydrochloride for the treatment of huntington's disease | |
| IL286703A (en) | Ghrh or analogues thereof for use in treatment of hepatic disease | |
| GB2574954B (en) | Tissue scaffold and scaffold composition | |
| HK1243709A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| EP3518951C0 (en) | Compositions for use in the treatment of osteoporis and bone fractures | |
| IL272495A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| PL3352742T3 (en) | Compositions comprising triterpenoids for the treatment of alzheimer's disease and parkinson's disease | |
| ES2660372T8 (en) | Substances and procedures for use in the prevention and / or treatment of Huntington's disease | |
| EP3137097C0 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| PT3137093T (en) | Treatment and prevention of alzheimer's disease (ad) | |
| PT3137094T (en) | Treatment and prevention of alzheimer's disease (ad) | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201802374D0 (en) | Tissue stain and use thereof | |
| GB201521442D0 (en) | Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders | |
| ITUA20163037A1 (en) | Formulations for use in the treatment or prevention of urological disorders | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
| IT201700083444A1 (en) | Composition for the prevention and / or treatment of thyroid diseases |